Predictive And Prognostic Value Of Her2 Gene Expression And Her2 Amplification In Patients With Metastatic Colorectal Cancer (Mcrc) Enrolled In Calgb/Swog 80405 (Alliance).

Francesca Battaglin,Fang-Shu Ou,Xueping Qu,Monica M. Bertagnolli,Howard S. Hochster,Donna Niedzwiecki,Richard M. Goldberg,Robert J. Mayer,Tyler J. Zemla,Charles David Blanke,Alan P. Venook,Omar Kabbarah,Heinz-Josef Lenz,Federico Innocenti

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 1|浏览31

暂无评分

摘要

4086Background: The randomized phase III CALGB/SWOG 80405 trial found no difference in overall survival (OS) in first-line mCRC pts treated with either bevacizumab (Bev) or cetuximab (Cet) combined...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要